| 71.89 0.14 (0.2%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 86.61 | 1-year : | 101.17 |
| Resists | First : | 74.16 | Second : | 86.61 |
| Pivot price | 71.51 |
|||
| Supports | First : | 69.12 | Second : | 66.01 |
| MAs | MA(5) : | 72.62  |
MA(20) : | 70.73 |
| MA(100) : | 60.65 |
MA(250) : | 55.31 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 67.1 |
D(3) : | 76.4 |
| RSI | RSI(14): 62.2 |
|||
| 52-week | High : | 74.16 | Low : | 43.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GMED ] has closed below upper band by 44.0%. Bollinger Bands are 6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 73.12 - 73.57 | 73.57 - 73.99 |
| Low: | 70.61 - 71.13 | 71.13 - 71.62 |
| Close: | 71.1 - 71.86 | 71.86 - 72.59 |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Fri, 26 Jul 2024
Globus Medical, Inc. (NYSE:GMED) Shares Sold by Vanguard Group Inc. - MarketBeat
Fri, 26 Jul 2024
Vanguard Group Inc. Sells 323,041 Shares of Globus Medical, Inc. (NYSE:GMED) - Defense World
Thu, 25 Jul 2024
Globus Medical, Inc. (NYSE:GMED) Shares Sold by Natixis - MarketBeat
Thu, 25 Jul 2024
Globus Medical (NYSE:GMED) Hits New 12-Month High at $74.05 - Defense World
Thu, 25 Jul 2024
Globus Medical Gains FDA Clearance for New Knee Surgery Technology - MSN
Tue, 23 Jul 2024
Orion Portfolio Solutions LLC Purchases 1,837 Shares of Globus Medical, Inc. (NYSE:GMED) - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 113 (M) |
| Shares Float | 112 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 103.6 (%) |
| Shares Short | 7,160 (K) |
| Shares Short P.Month | 7,040 (K) |
| EPS | 0.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.04 |
| Profit Margin | 3.5 % |
| Operating Margin | 13.7 % |
| Return on Assets (ttm) | 5.2 % |
| Return on Equity (ttm) | 2.2 % |
| Qtrly Rev. Growth | 119.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 16.86 |
| EBITDA (p.s.) | 4.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 243 (M) |
| Levered Free Cash Flow | -308 (M) |
| PE Ratio | 133.12 |
| PEG Ratio | 1.5 |
| Price to Book value | 2.47 |
| Price to Sales | 4.26 |
| Price to Cash Flow | 33.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|